MedTrace Logo

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

NCT04161755 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.

Conditions

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)

BIOLOGICAL

RO7198457

RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)

DRUG

mFOLFIRINOX

mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)

Sponsors & Collaborators

Principal Investigators

  • Vinod Balachandran, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2026-11-11
Completion
2026-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161755 on ClinicalTrials.gov